Prespecified subgroup analysis found that the reduction in proportion of patients experiencing WHO Grade 2 to 4 bleeds ( main trial outcome ) seen in the prophylaxis arm was of greater magnitude in chemo/alloHSCT than autoHSCT patients ( interaction p = 0.04 ) .